Discovery and structure–activity relationships of urea derivatives as potent and novel CCR3 antagonists
摘要:
The synthesis and structure-activity relationships of ureas as CCR3 antagonists are described. Optimization starting with lead compound 2 (IC50 = 190 nM) derived from initial screening hit compound 1 (IC50 = 600 nM) led to the identification of (S)-N-((1R,3S,5S)-8-((6-fluoronaphthalen-2-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide 27 (IC50 = 4.9 nM) as a potent CCR3 antagonist. (c) 2012 Elsevier Ltd. All rights reserved.
A simple proline-based organocatalyst for the enantioselective reduction of imines using trichlorosilane as a reductant
摘要:
A simple and inexpensive proline-based organocatalyst was developed for the reduction of imines using trichlorosilane as a reductant. The reduction of N-aryl imines in the presence of 10 mol % of N-pivaloyl-L-proline anilide was carried out to give the corresponding amines in excellent yields (up to 99%) with high enantioselectivities (up to 93% ee). (C) 2012 Elsevier Ltd. All rights reserved.
A simple and inexpensive proline-based organocatalyst was developed for the reduction of imines using trichlorosilane as a reductant. The reduction of N-aryl imines in the presence of 10 mol % of N-pivaloyl-L-proline anilide was carried out to give the corresponding amines in excellent yields (up to 99%) with high enantioselectivities (up to 93% ee). (C) 2012 Elsevier Ltd. All rights reserved.
Discovery and structure–activity relationships of urea derivatives as potent and novel CCR3 antagonists
The synthesis and structure-activity relationships of ureas as CCR3 antagonists are described. Optimization starting with lead compound 2 (IC50 = 190 nM) derived from initial screening hit compound 1 (IC50 = 600 nM) led to the identification of (S)-N-((1R,3S,5S)-8-((6-fluoronaphthalen-2-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide 27 (IC50 = 4.9 nM) as a potent CCR3 antagonist. (c) 2012 Elsevier Ltd. All rights reserved.